Loading
Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma.
Ingo Mellinghoff was principal investigator of INDIGO, which showed the dual IDH1/2 inhibitor vorasidenib more than doubles progression-free survival and delays the need for chemoradiotherapy in grade 2 IDH-mutant glioma, the first targeted drug approved for glioma and a shift away from early radiation for young patients. His laboratory studies signalling and metabolism in glioma and he leads neuro-oncology drug development at MSKCC.
| Title | Journal | Year |
|---|---|---|
| Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO) | NEJM | 2023 |
| Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial | Clinical Cancer Research | 2021 |
Shares INDIGO, Vorasidenib, Glioma & glioblastoma and the tag glioma.
Shares INDIGO, Vorasidenib, IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome.
Shares IDH1 / IDH2, Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Memorial Sloan Kettering Cancer Center and the tag idh.
Shares Vorasidenib, IDH1 / IDH2 and the tag idh.
Shares Vorasidenib, IDH1 / IDH2, Glioma & glioblastoma and the tag idh.
Shares Vorasidenib, Glioma & glioblastoma and the tag glioma.
Shares Glioma & glioblastoma and the tag glioma.
Shares Memorial Sloan Kettering Cancer Center and the tag targeted-therapy.